WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

Home・Elenco Azioni・Compass Pathways Plc ADR

Compass Pathways Plc ADR

Chiusa

9.56 4.82

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

9.35

Massimo

9.56

Metriche Chiave
By Trading Economics
Entrata	44M -94M
Dipendenti	156
EBITDA	91M -46M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+127.87% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	670M 1.3B
Apertura precedente	4.74
Chiusura precedente	9.56

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

3.645 / 4.0539 Supporto e resistenza

Compass Pathways Plc ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 apr 2026, 19:19 UTC

Acquisizioni, Fusioni, Takeovers

Intertek Group Rejects EQT's Revised Offer

24 apr 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Scoring the Cook Era -- Barrons.com

24 apr 2026, 20:51 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:50 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Financial Services Roundup: Market Talk

24 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

24 apr 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:09 UTC

Utili

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr 2026, 19:48 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr 2026, 19:25 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 19:25 UTC

Acquisizioni, Fusioni, Takeovers

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr 2026, 19:22 UTC

Utili

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr 2026, 19:06 UTC

Utili

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr 2026, 19:05 UTC

Discorsi di Mercato

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr 2026, 18:30 UTC

Acquisizioni, Fusioni, Takeovers

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr 2026, 18:28 UTC

Acquisizioni, Fusioni, Takeovers

Intertek Rejects Revised EQT Offer

24 apr 2026, 18:12 UTC

Discorsi di Mercato

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr 2026, 18:06 UTC

Discorsi di Mercato

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr 2026, 17:42 UTC

Utili

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr 2026, 17:28 UTC

Utili

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr 2026, 17:28 UTC

Discorsi di Mercato

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr 2026, 17:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

24 apr 2026, 17:11 UTC

Discorsi di Mercato

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr 2026, 17:09 UTC

Discorsi di Mercato

Utili

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr 2026, 17:09 UTC

Acquisizioni, Fusioni, Takeovers

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 17:06 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr 2026, 16:51 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr 2026, 16:20 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

24 apr 2026, 16:20 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Financial Services Roundup: Market Talk

24 apr 2026, 16:20 UTC

Discorsi di Mercato

Utili

Auto & Transport Roundup: Market Talk

24 apr 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Compass Pathways Plc ADR Previsione

Obiettivo di Prezzo

By TipRanks

127.87% in crescita

Previsioni per 12 mesi

Media 21.83 USD 127.87%

Alto 70 USD

Basso 8 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Compass Pathways Plc ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Compass Pathways Plc ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

3.645 / 4.0539Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Compass Pathways Plc ADR

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.